Skip to main content

Advertisement

SpringerLink
Log in

From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?

  • Lung Cancer (HA Wakelee, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

An Erratum to this article was published on 20 December 2016

Opinion statement

New treatments—as immunotherapies and new antiangiogenic agents—are now available in second-line setting for patients affected by EGFR wild-type and ALK-negative non-small-cell lung cancer (NSCLC). Nintedanib, ramucirumab, nivolumab and pembrolizumab have to be included in the therapeutic sequences for patients affected by NSCLC, but no clear selection criteria are to date offered, except for patients with PD-L1 expression ≥50 %. Performance status, smoking habits and comorbidities should be considered as clinical criteria in order to select the appropriate treatment, but also tumour characteristics as histotype, platinum resistance and rapid progression after a first-line therapy should be taken into account. The aim of the present paper is to identify subgroups of patients eligible for different therapy sequences.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10):2095–103.

    CAS  PubMed  Google Scholar 

  2. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol. 2000;18(12):2354–62.

    CAS  PubMed  Google Scholar 

  3. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589–97.

    Article  CAS  PubMed  Google Scholar 

  4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123–32.

    Article  CAS  PubMed  Google Scholar 

  5. Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–94.

    Article  CAS  PubMed  Google Scholar 

  6. Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2):143–55 Randomized placebo-controlled trial showing nintedanib efficacy in second-line setting in squamous and nonsquamous NSCLC.

    Article  CAS  PubMed  Google Scholar 

  7. Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665–73 Randomized placebo-controlled trial showing ramucirumab efficacy in second-line setting in squamous and nonsquamous NSCLC.

    Article  CAS  PubMed  Google Scholar 

  8. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35 Phase III trial comparing nivolumab with docetaxel in squamous NSCLC.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39 Phase III trial comparing nivolumab with docetaxel in nonsquamous NSCLC.

    Article  CAS  PubMed  Google Scholar 

  10. Garon EB, Rizvi NA, Hui R, Leighl N, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28 Phase I trial demonstrating pembrolizumab efficacy in PD-L1 positive patients independently from hystotype.

    Article  PubMed  Google Scholar 

  11. Peterson P, Park K, Fossella F, Gatzemeier U, John W, Scagliotti G. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol. 2007. doi:10.1097/01.JTO.0000284677.33344.62.

    Google Scholar 

  12. Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013;14(10):981–8.

    Article  CAS  PubMed  Google Scholar 

  13. Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, et al. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: docetaxel and erlotinib lung cancer trial (DELTA). J Clin Oncol. 2014;32(18):1902–8.

    Article  CAS  PubMed  Google Scholar 

  14. Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, et al. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer. 2013;119(15):2754–64.

    Article  CAS  PubMed  Google Scholar 

  15. Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012;13(3):300–8.

    Article  CAS  PubMed  Google Scholar 

  16. Gregorc V, Novello S, Lazzari C, Barni S, Aieta M, Mencoboni M, et al. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. Lancet Oncol. 2014;15:713–21.

    Article  CAS  PubMed  Google Scholar 

  17. Carbone DP, Ding K, Roder H, Grigorieva J, Roder J, Tsao M-S, Seymour L, Shepherd FA. Prognostic and predictive role of the VeriStrat® plasma test in patients with advanced non-small cell lung cancer treated with erlotinib or placebo in the NCIC clinical trials group BR.21 trial. J Thorac Oncol. 2012;7(11):1653–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer). Lancet. 2005;366(9496):1527–37.

    Article  CAS  PubMed  Google Scholar 

  19. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372(9652):1809–18.

    Article  CAS  PubMed  Google Scholar 

  20. Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol. 2008;26(26):4244–52.

    Article  CAS  PubMed  Google Scholar 

  21. Lee DH, Park K, Kim JH, Lee JS, Shin SW, et al. Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res. 2010;16(4):1307–14.

    Article  CAS  PubMed  Google Scholar 

  22. Soria JC, Felip E, Cobo M, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2015;16(8):897–907.

    Article  CAS  PubMed  Google Scholar 

  23. Shaked Y, Henke E, Roodhart JM, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell. 2008;14(3):263–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Shaked Y, Ciarrocchi A, Franco M, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science. 2006;313(5794):1785–7.

    Article  CAS  PubMed  Google Scholar 

  25. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50.

    Article  CAS  PubMed  Google Scholar 

  26. Sheng J, Yang YP, Yang BJ, et al. Efficacy of addition of antiangiogenic agents to taxanes-containing chemotherapy in advanced nonsmall-cell lung cancer: a meta-analysis and systemic review. Medicine (Baltimore). 2015;94(31):e1282.

    Article  CAS  Google Scholar 

  27. Sheng J, Yang Y, Ma Y, et al. The efficacy of combining antiangiogenic agents with chemotherapy for patients with advanced non-small cell lung cancer who failed first-line chemotherapy: a systematic review and meta-analysis. PLoS One. 2015;10(6):e0127306.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Zhao L, Li W, Zhang H, Hou N, Guo L, Gao Q. Angiogenesis inhibitors rechallenge in patients with advanced non-small-cell lung cancer: a pooled analysis of randomized controlled trials. Onco Targets Ther. 2015;8:2775–81.

    PubMed  PubMed Central  Google Scholar 

  29. Hanna NH, Kaiser R, Sullivan RN, et al. Lume-lung 2: a multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous nonsmall cell lung cancer (NSCLC) after failure of first-line chemotherapy. ASCO Meeting Abstracts. 2013;31:8034.

    Google Scholar 

  30. Kaiser R, Barrueco J, Reck M, et al. Identification of a clinical biomarker for 2nd line combination with nintedanib in adenocarcinoma non-small cell lung cancer (NSCLC) patients in two phase III trials. Eur J Cancer 2013;49:abstract 3479.

  31. Krzakowski M, Mellemgaard A, Orlov S, et al. Prior taxane use in the LUME-Lung 1 phase III trial and the effect on outcome following 2nd-line treatment with nintedanib (BIBF 1120) and docetaxel in patients with advanced NSCLC [abstr no. 473P]. Ann Oncol. 2014;25(suppl 4):iv158.

    Google Scholar 

  32. Mellemgaard A, Orlov S, Krzakowski M, et al. Effect of nintedanib (BIBF 1120) combined with standard 2nd-line docetaxel in NSCLC patients who received prior pemetrexed in LUME-Lung 1: a randomized, placebo-controlled phase III trial [abstr no. 471P]. Ann Oncol. 2014;25(suppl 4):iv157.

    Google Scholar 

  33. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015. doi:10.1016/S0140-6736(15)01281-7.

    Google Scholar 

  34. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837–46 Phase III trial comparing atezolizumab with docetaxel in nonsquamous and squamous NSCLC.

    Article  CAS  PubMed  Google Scholar 

  35. Gainor JF, Sequist LV, Shaw AT et al. Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC). J Clin Oncol. 2015 ASCO Annual Meeting (May 29–June 2, 2015).Vol 33, No 15_suppl (May 20 Supplement), 2015: 8012.

  36. P. Mitchell et al. Programmed death ligand-1 (PDL-1) expression in non-small cell lung cancer (NSCLC): analysis of a large early stage cohort; and concordance of expression in paired primary-nodal and primary-metastasis tumour samples. J Thorac Oncol 2015; 10 [suppl; S199 abstr].

  37. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL(MO22089). J Clin Oncol. 2013;31(24):3004–11.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Catholic University of Sacred Heart, Largo A. Gemelli, 8, 00168, Rome, Italy

    Ettore D’Argento MD, PhD, Giovanni Schinzari MD, PhD, Antonia Strippoli MD, PhD, Michele Basso MD, PhD, Alessandra Cassano MD, PhD & Carlo Barone MD, PhD

  2. Department of Medical Oncology, Humanitas Clinical and Research Center, Via Manzoni, 56, 20089, Rozzano, MI, Italy

    Sabrina Rossi MD

Authors
  1. Ettore D’Argento MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sabrina Rossi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giovanni Schinzari MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antonia Strippoli MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michele Basso MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alessandra Cassano MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Carlo Barone MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sabrina Rossi MD.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Lung Cancer

An erratum to this article is available at http://dx.doi.org/10.1007/s11864-016-0441-1.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

D’Argento, E., Rossi, S., Schinzari, G. et al. From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?. Curr. Treat. Options in Oncol. 17, 59 (2016). https://doi.org/10.1007/s11864-016-0437-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-016-0437-x

Keywords

Search

Navigation